• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Medical Experts Urge FDA to be Tougher on COVID-19 Vaccine Trial Monitoring

Medical Experts Urge FDA to be Tougher on COVID-19 Vaccine Trial Monitoring

October 12, 2020

Dozens of medical experts from across the nation have written a letter to FDA Commissioner Stephen Hahn, Center for Biologics Evaluation and Research (CBER) Director Peter Marks and the FDA’s vaccine advisory committee calling for stronger requirements for monitoring participants in COVID-19 vaccine trials.

The letter comes on the heels of the agency’s publication last week of guidance — despite a threatened block from the White House — that outlines more stringent Emergency Use Authorization (EUA) requirements for COVID-19 vaccines.

The 62 experts who signed the letter took issue with the guidance requiring a median of at least two months of safety observation of trial participants after vaccination, arguing it doesn’t set the bar high enough.

They implored the agency to require a minimum of two months of safety observation for all trial participants. Without that requirement, a vaccine could receive authorization before many trial participants have been monitored through the period when most adverse events are seen, the experts wrote.

“There is too much at stake. Authorization of a vaccine before a high safety bar is met would severely erode public trust and set back efforts to achieve widespread vaccination. In short, premature authorization would prolong the pandemic, with disastrous consequences,” they wrote. Signers of the letter included Gail D’Onofrio, the chair of Yale University’s Department of Emergency Medicine, Tom Inglesby, director of Johns Hopkins’ Center for Health Security, and Robert Truog, director of Harvard University’s Center for Bioethics.

Concerns abound that the FDA could cave to political pressure in its efforts to verify a COVID-19 vaccine’s safety and effectiveness, and authorize one before it has proven itself in a late-stage trial. While the White House allegedly blocked the EUA guidance because the industry took issue with it, former FDA Commissioner Scott Gottlieb said he was unaware of any industry pushback and Pfizer CEO Albert Bourla said that his company had never discussed the guidelines with the White House.

Read the letter here: https://bit.ly/2SF4z4r.

COVID-19
    • Related Directories

      Olumiant (baricitinib)

      Veklury (remdesivir)

      Comirnaty (COVID-19 Vaccine, mRNA)

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing